CLINICAL PRACTICE GUIDELINE: CYP2D6 GENOTYPING FOR SAFE AND EFFICACIOUS CODEINE THERAPY

被引：0
|
作者：
Madadi, Parvaz [1 ]
Amstutz, Ursula [2 ,3 ,4 ]
Rieder, Michael [5 ,6 ,7 ]
Ito, Shinya [1 ]
Fung, Vincent [8 ,9 ,10 ,11 ]
Hwang, Soomi [3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Turgeon, Jacques [12 ,13 ]
Michaud, Veronique [12 ,13 ]
Koren, Gideon [1 ,5 ,6 ,7 ]
Carleton, Bruce C. [2 ,3 ,4 ]
机构：
[1] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Dept Pediat, Toronto, ON, Canada
[2] Univ British Columbia, Div Translat Therapeut, Dept Pediat, Vancouver, BC, Canada
[3] BC Childrens Hosp, Pharmaceut Outcomes Programme, Vancouver, BC, Canada
[4] Child & Family Res Inst, Vancouver, BC, Canada
[5] Univ Western Ontario, Schulich Sch Med & Dent, Dept Med, Clin Pharmacol, London, ON, Canada
[6] Univ Western Ontario, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON, Canada
[7] Univ Western Ontario, Schulich Sch Med & Dent, Dept Pediat, London, ON, Canada
[8] Prohlth Clin Res Ctr, Vancouver, BC, Canada
[9] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
[10] Univ British Columbia, Fac Med, Dept Family Med, Vancouver, BC, Canada
[11] Univ British Columbia, Fac Med, Dept Pathol & Lab Med, Vancouver, BC, Canada
[12] Ctr Hosp Univ Montreal, Univ Montreal Hosp Ctr CRCHUM, Res Ctr, Montreal, PQ, Canada
[13] Univ Montreal, Fac Pharm, Montreal, PQ, Canada
来源：
JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY | 2013年 / 20卷 / 03期
基金：
加拿大健康研究院;
关键词：
Codeine; morphine; pharmacogenetics; CYP2D6; guidelines;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
This guideline is intended to provide a basis for informed decision-making regarding genetic testing to identify those individuals who will not benefit from codeine therapy, as well as those who are at an increased risk for codeine-induced toxicity. This guideline addresses the following key questions: 1) Should genetic testing for CYP2D6 be performed in patients prior to the initiation of codeine therapy? 2) How should patients with an indication for codeine therapy be managed based on their genotyping results for CYP2D6?
引用
收藏
页码：E369 / E396
页数：28
相关论文
共 50 条
  • [41] Functional phenotyping of the CYP2D6 probe drug codeine in the horse
    Gretler, S. R.
    Finno, C. J.
    Kass, P. H.
    Knych, H. K.
    BMC VETERINARY RESEARCH, 2021, 17 (01)
  • [42] Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer
    Susce, Margaret T.
    Murray-Carmichael, Elaina
    de Leon, Jose
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (07): : 1356 - 1358
  • [43] Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype
    Mikus, G
    Trausch, B
    Rodewald, C
    Hofmann, U
    Richter, K
    Gramatte, T
    Eichelbaum, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (04) : 459 - 466
  • [44] Codeine abuse liability is modified by CYP2D6 inhibition.
    Romach, MK
    Kathiramalainathan, K
    Kaplan, HL
    Busto, UE
    Tyndale, RF
    Sellers, EM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PI107 - PI107
  • [45] Interaction between CYP2D6 inhibitor antidepressants and codeine: is this relevant?
    Cazet, Lucie
    Bulteau, Samuel
    Evin, Adrien
    Spiers, Andrew
    Caillet, Pascal
    Kuhn, Emmanuelle
    Pivette, Jacques
    Chaslerie, Anicet
    Jolliet, Pascale
    Victorri-Vigneau, Caroline
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (08) : 879 - 886
  • [46] CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Berry, Donald
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (17): : 1267 - 1269
  • [47] Eliglustat and CYP2D6 genotyping prior to initiation of therapy: frequencies of CYP2D6 phenotype across French patients with type 1 Gaucher disease
    Verstuyft, C.
    Dupuis, E.
    Arkoub, Z. Ait
    Saujot, C.
    Lamour, L.
    Camou, F.
    Belmatoug, N.
    Becquemont, L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 43 - 43
  • [48] CYP2D6 genotyping by a multiplex primer extension reaction
    Sistonen, J
    Fuselli, S
    Levo, A
    Sajantila, A
    CLINICAL CHEMISTRY, 2005, 51 (07) : 1291 - 1295
  • [49] CYP2D6 genotyping prior to starting tamoxifen treatment
    Kloft C.
    best practice onkologie, 2018, 13 (6) : 325 - 329
  • [50] DEBRISOQUINE HYDROXYLATION (CYP2D6) PHENOTYPE ASSIGNMENT BY GENOTYPING
    DALY, AK
    ARMSTRONG, M
    MONKMAN, SC
    IDLE, ME
    IDLE, JR
    AMERICAN JOURNAL OF HUMAN GENETICS, 1991, 49 (04) : 110 - 110
12345